Immunome (NASDAQ:IMNM) Price Target Cut to $25.00 by Analysts at Guggenheim

Immunome (NASDAQ:IMNM - Get Free Report) had its target price lowered by Guggenheim from $35.00 to $25.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price target suggests a potential upside of 206.75% from the stock's current price.

Several other research firms also recently commented on IMNM. Wedbush restated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $25.50.

Immunome Trading Down 0.4 %

Immunome stock traded down $0.03 on Thursday, reaching $8.15. 960,264 shares of the stock were exchanged, compared to its average volume of 827,037. Immunome has a twelve month low of $8.12 and a twelve month high of $26.70. The firm has a fifty day moving average price of $9.72 and a two-hundred day moving average price of $11.49. The stock has a market cap of $650.18 million, a PE ratio of -1.00 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Equities analysts anticipate that Immunome will post -2.21 EPS for the current fiscal year.

Remove Ads

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the business's stock in a transaction on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. grew its holdings in Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after acquiring an additional 237,497 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Immunome during the third quarter worth approximately $219,000. Primecap Management Co. CA lifted its position in shares of Immunome by 4.5% during the third quarter. Primecap Management Co. CA now owns 280,800 shares of the company's stock worth $4,105,000 after purchasing an additional 12,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock valued at $6,469,000 after purchasing an additional 302,916 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock valued at $776,000 after purchasing an additional 5,043 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.